Literature DB >> 29150199

Medications for opioid use disorder: bridging the gap in care.

Nora D Volkow1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29150199     DOI： 10.1016/S0140-6736(17)32893-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  26 in total

1.  Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.

Authors:  Laura Brandt; Jermaine D Jones; Suky Martinez; Jeanne M Manubay; Shanthi Mogali; Tatiana Ramey; Frances R Levin; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

2.  Extended-release naltrexone overlooked in opioid use disorders guideline.

Authors:  Launette M Rieb
Journal:  CMAJ       Date:  2018-07-16       Impact factor: 8.262

3.  Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.

Authors:  Lesia M Ruglass; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Skye Fitzpatrick; Celestina Barbosa-Leiker; Kathleen Burlew; Shelly F Greenfield; John Rotrosen; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2019-10-21       Impact factor: 4.492

4.  Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys.

Authors:  Stephen J Kohut; Jack Bergman
Journal:  Eur J Pharmacol       Date:  2018-09-27       Impact factor: 4.432

5.  Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS).

Authors:  Laramie R Smith; Maria Luisa Mittal; Karla Wagner; Michael M Copenhaver; Chinazo O Cunningham; Valerie A Earnshaw
Journal:  Addiction       Date:  2019-11-27       Impact factor: 6.526

6.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

7.  Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis.

Authors:  Nicholas Baldwin; Roger Gray; Anirudh Goel; Evan Wood; Jane A Buxton; Launette Marie Rieb
Journal:  Drug Alcohol Depend       Date:  2018-02-20       Impact factor: 4.492

8.  Assessment and Management of Endocarditis Among People Who Inject Drugs in the General Hospital Setting.

Authors:  Joji Suzuki
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

9.  Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder.

Authors:  Brian D Kiluk; Sarah W Yip; Elise E DeVito; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  Clin Psychol Sci       Date:  2019-09-23

10.  Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.

Authors:  Kathleen M Carroll; Charla Nich; Tami L Frankforter; Sarah W Yip; Brian D Kiluk; Elise E DeVito; Mehmet Sofuoglu
Journal:  Drug Alcohol Depend       Date:  2018-10-04       Impact factor: 4.492
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.